emegency notice!

On May 27, the Hunan Provincial Public Resources Trading Center issued the "Emergency Notice on the Handling of Pharmaceutical Enterprises that Have Not Uploaded a Credit Commitment Letter"

It is worth noting that the list of unsubmitted commitments disclosed by Hunan involves 1959 pharmaceutical companies, of which 77 are pharmaceutical manufacturers and the rest are medical device companies

Commitment not submitted

Tens of thousands of enterprises in the industry to be named

June 1 seems to be the deadline for the fate of tens of thousands of pharmaceutical companies

After sorting out, there are many well-known domestic and foreign pharmaceutical companies such as GlaxoSmithKline (China) Investment Co.

However, the methods of handling pharmaceutical companies that have not uploaded the Credit Commitment in accordance with the regulations are slightly different.

  The provincial procurement platform requires pharmaceutical companies to upload the "Credit Commitment" in a timely manner, which is the follow-up designated action of the implementation plan of the "National Medical Security Administration's Guiding Opinions on Establishing a Pharmaceutical Price and Recruitment Credit Evaluation System" (hereinafter referred to as the "Guiding Opinions")

Strokes in the promises have to open a ticket

Force the industry to purify and upgrade

  According to the deployment of the "Guiding Opinions", the provincial centralized procurement agencies adopt written reminders and warnings based on the credit ratings of pharmaceutical enterprises, rely on the centralized procurement platform to prompt the purchaser of risk information, restrict or suspend the listing of relevant drugs or medical consumables, and restrict or suspend procurement related drugs or medical supplies, and other information disclosure measures to deal with dishonesty

  In April of this year, the Zhejiang Pharmaceutical Equipment Procurement Center issued a notice stating that according to the relevant facts disclosed in the local court’s judgment, Harbin Yuheng Pharmaceutical Co.

  Subsequently, the National Medical Insurance Bureau stated that Zhejiang Province notified the credit evaluation results of a certain company Lugua Polypeptide Injection and suspended online transactions.

  The industry generally believes that outstanding problems such as rebates and monopoly price increases in the pharmaceutical sector have long existed, which are an important reason for the inflated prices of medicines, and have led to problems such as excessive growth of medical expenses and massive losses of medical insurance funds

  Taking the issue of drug rebates as an example, according to the statistics of publicly available court judgments, from 2016 to 2019, more than half of the 100 compulsory drug companies nationwide were found to have given or indirectly given rebates, of which the most frequent companies were involved in the case for three years There were more than 20 cases, and the rebate amount in a single case exceeded 20 million yuan

  In the view of industry insiders, although the implementation of the establishment of medical price and recruitment credit evaluation system has increased restrictions on enterprises, it effectively protects the interests of medical institutions and the public; strengthens the service awareness of enterprises, parallels online and offline, and standardizes the market environment.